Fed. Circ. Keeps Sandoz's Enbrel Biosimilar Off The Market
Amgen Inc. on Wednesday fended off competition to its top-selling biologic Enbrel, when the Federal Circuit rejected Sandoz Inc.'s arguments that two patents are invalid for double-patenting....To view the full article, register now.
Already a subscriber? Click here to view full article